Smithfield Trust Co. cut its position in shares of Core Laboratories (NYSE:CLB) by 33.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,879 shares of the oil and gas company’s stock after selling 963 shares during the quarter. Smithfield Trust Co.’s holdings in Core Laboratories were worth $218,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Dupont Capital Management Corp lifted its holdings in Core Laboratories by 40.0% during the 3rd quarter. Dupont Capital Management Corp now owns 12,050 shares of the oil and gas company’s stock worth $1,396,000 after buying an additional 3,444 shares during the last quarter. Janney Montgomery Scott LLC lifted its holdings in Core Laboratories by 9.9% during the 3rd quarter. Janney Montgomery Scott LLC now owns 19,844 shares of the oil and gas company’s stock worth $2,299,000 after buying an additional 1,788 shares during the last quarter. Bbva Compass Bancshares Inc. lifted its holdings in Core Laboratories by 8.4% during the 3rd quarter. Bbva Compass Bancshares Inc. now owns 11,524 shares of the oil and gas company’s stock worth $1,335,000 after buying an additional 897 shares during the last quarter. Synovus Financial Corp lifted its holdings in Core Laboratories by 19.6% during the 3rd quarter. Synovus Financial Corp now owns 6,764 shares of the oil and gas company’s stock worth $783,000 after buying an additional 1,108 shares during the last quarter. Finally, Parallel Advisors LLC lifted its holdings in Core Laboratories by 73.3% during the 3rd quarter. Parallel Advisors LLC now owns 1,634 shares of the oil and gas company’s stock worth $189,000 after buying an additional 691 shares during the last quarter.

A number of research firms have commented on CLB. Stifel Nicolaus raised Core Laboratories from a “hold” rating to a “buy” rating and reduced their target price for the stock from $117.00 to $110.00 in a report on Monday, October 29th. Edward Jones began coverage on Core Laboratories in a report on Tuesday, September 4th. They set a “buy” rating on the stock. Morgan Stanley began coverage on Core Laboratories in a report on Tuesday, September 18th. They set an “equal weight” rating and a $125.00 target price on the stock. Bank of America began coverage on Core Laboratories in a report on Wednesday, October 17th. They set a “neutral” rating on the stock. Finally, TheStreet downgraded Core Laboratories from a “b-” rating to a “c+” rating in a report on Thursday, October 25th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $111.36.

Shares of NYSE CLB opened at $85.48 on Friday. The company has a market capitalization of $3.92 billion, a P/E ratio of 42.74, a P/E/G ratio of 2.64 and a beta of 1.64. Core Laboratories has a 12-month low of $82.07 and a 12-month high of $130.34. The company has a debt-to-equity ratio of 1.83, a quick ratio of 1.85 and a current ratio of 2.31.

Core Laboratories (NYSE:CLB) last announced its quarterly earnings results on Wednesday, October 24th. The oil and gas company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.63 by $0.01. The business had revenue of $182.15 million for the quarter, compared to the consensus estimate of $178.11 million. Core Laboratories had a return on equity of 68.00% and a net margin of 13.21%. The business’s revenue was up 11.8% on a year-over-year basis. During the same quarter last year, the business posted $0.46 EPS. On average, research analysts forecast that Core Laboratories will post 2.26 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, November 20th. Investors of record on Friday, October 19th will be issued a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 2.57%. The ex-dividend date of this dividend is Thursday, October 18th. Core Laboratories’s dividend payout ratio (DPR) is 110.00%.

ILLEGAL ACTIVITY WARNING: “Smithfield Trust Co. Has $218,000 Position in Core Laboratories (CLB)” was first published by Daily Political and is owned by of Daily Political. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2018/11/10/smithfield-trust-co-has-218000-position-in-core-laboratories-clb.html.

About Core Laboratories

Core Laboratories N.V. provides reservoir description, and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates in two segments, Reservoir Description and Production Enhancement segments. The Reservoir Description segment comprises the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs.

Further Reading: Insider Trading – What You Need to Know

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories (NYSE:CLB).

Institutional Ownership by Quarter for Core Laboratories (NYSE:CLB)

Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.